Esperance is located in Houston, Texas near the Texas Medical Center, the largest medical complex in the world with over eight million annual patient visits, >9000 hospital visits, and home to 59 preeminent health care and educational institutions including MD Anderson Cancer Center, Esperance’s Strategic Partner and the number one rated cancer center in the world.
Targeted Cancer Therapeutics
Esperance is developing a novel class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific targets such as receptors on the surface of cancer cells. The products also seek and destroy dividing and non-dividing cancer cells including cells known to be resistant to chemotherapeutics.
Novel Approach and Technology
- Proprietary discovery and development expertise
- Cationic Lytic Peptide (CLYPTM) technology platform
- Targeted Membrane Disrupting Peptides (MDPs)
- Antibody Drug Conjugates (ADCs)